Clinitech FY26 net profit rises 7% to ₹42.25 lakh

Clinitech Laboratory reported a 7% increase in net profit to ₹42.25 lakh for the financial year ended March 31, 2026, compared to ₹39.47 lakh in the previous year. Revenue from operations grew 15% to ₹947.50 lakh from ₹823.49 lakh in FY25. The Board of Directors approved the audited standalone and consolidated financial results at a meeting held on May 28, 2026.

Financial Performance

The company’s total income for FY26 stood at ₹966.31 lakh, up from ₹846.26 lakh in the previous year. Total expenses increased to ₹905.93 lakh from ₹790.79 lakh. The basic earnings per share (EPS) for the year was ₹1.85, slightly lower than ₹1.90 in the prior year. For the half-year ended March 31, 2026, the company reported a profit after tax of ₹12.23 lakh.

Consolidated Results

On a consolidated basis, net profit for the year attributable to the owners of the parent company rose to ₹41.79 lakh from ₹39.47 lakh in FY25. Total consolidated revenue from operations reached ₹949.12 lakh, compared to ₹823.49 lakh in the previous year. Consolidated total income for the year was ₹967.93 lakh.

Capital Allocation and Cash Flows

The company’s cash and cash equivalents decreased to ₹206.46 lakh as of March 31, 2026, from ₹307.48 lakh a year earlier. Net cash generated from operating activities was negative at ₹89.55 lakh, while investing activities resulted in a net outflow of ₹43.99 lakh. The company raised ₹35.76 lakh from long-term borrowings during the year.

Regulatory Compliance

The statutory auditors, M/s Kale Malde & Co., issued an audit report with an "unmodified opinion" on the standalone and consolidated financial statements. The company also submitted a certificate regarding the utilization of IPO proceeds, confirming that ₹528.30 lakh had been utilized out of the total ₹578.30 lakh raised. The intimation regarding the board meeting was submitted to BSE Limited pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
0.0%	0.0%	-8.36%	-12.90%	-10.21%	-68.70%

Clinitech laboratory Limited has formally notified BSE Limited about the non-applicability of Related Party Transactions regulations for the financial year 2026. The company submitted an official undertaking on April 22, 2026, confirming its compliance status under SEBI regulations.

Regulatory Exemption Details

The company has confirmed that Related Party Transactions under Regulation 23 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 do not apply to its operations for the half year and financial year ended March 31, 2026. This exemption is based on the company's listing status and transaction volumes.

Parameter:	Details
Applicable Period:	Half year and financial year ended March 31, 2026
Listing Platform:	BSE SME Portal
Exemption Regulation:	Regulation 15 of SEBI LODR Regulations, 2015
Threshold Status:	Below specified limits

SME Portal Listing Benefits

As a company listed under BSE's Small and Medium Enterprises (SME) portal, Clinitech Laboratory Limited enjoys certain regulatory relaxations. The company does not exceed the threshold limit specified under the regulations, making it eligible for exemption from certain Related Party Transaction disclosure requirements.

Corporate Communication

The undertaking was addressed to the Assistant General Manager of the Department of Corporate Services at BSE Limited. The formal communication ensures transparency and regulatory compliance while informing the exchange about the company's current status regarding Related Party Transactions.

Management Authorization

The undertaking was digitally signed and authorized by Jagdish Umakant Nayak, Chairman and Managing Director of the company, on April 22, 2026. This formal authorization demonstrates the company's commitment to maintaining proper corporate governance and regulatory compliance standards.